Brian Cheng
Stock Analyst at JP Morgan
(0)
# 4805
Out of 5,358 analysts
71
Total ratings
33.96%
Success rate
-19.97%
Average return
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
BPMC Blueprint Medicines | Downgrades: Neutral | 130 129 | 127.82 | 0.92% | 3 | Jun 2, 2025 | |
ITOS ITeos Therapeutics | Downgrades: Neutral | 15 8 | 10.19 | -21.49% | 4 | May 13, 2025 | |
CGON CG Oncology | Initiates Coverage On: Overweight | 41 | 26.9 | 52.42% | 1 | May 2, 2025 | |
AAPG Ascentage Pharma Gro... | Initiates Coverage On: Overweight | n/a | n/a | n/a | 1 | Mar 27, 2025 | |
PTGX Protagonist Therapeu... | Maintains: Overweight | 53 57 | 54.41 | 4.76% | 5 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 45 13 | 8.06 | 61.29% | 4 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | n/a | n/a | n/a | 2 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | n/a | n/a | n/a | 3 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 18 | 12.59 | 42.97% | 2 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 27 28 | 9.65 | 190.16% | 4 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 51 46 | 16.77 | 174.3% | 2 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 39 33 | 3.41 | 867.74% | 2 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 16 6 | 1.74 | 244.83% | 2 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 24 | 9.13 | 162.87% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | n/a | n/a | n/a | 2 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Neutral | 5 | 0.39 | 1182.05% | 3 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 9 8 | 1.43 | 459.44% | 3 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 16 15 | 11.22 | 33.69% | 6 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 17 14 | 0.48 | 2816.67% | 3 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Neutral | n/a | n/a | n/a | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 20 6 | 0.75 | 700% | 2 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | n/a | n/a | n/a | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | n/a | n/a | n/a | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | n/a | n/a | n/a | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 24 | n/a | n/a | 1 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 33 39 | n/a | n/a | 2 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 20 | 8.2 | 143.9% | 2 | Sep 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 71 85 | 12.77 | 565.62% | 2 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 21 | 11.04 | 90.22% | 1 | Aug 3, 2021 |